Search

Your search keyword '"Harel, S."' showing total 652 results
Start Over Author "Harel, S."
652 results on '"Harel, S."'

1. Surfaces and equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the emergency department at a university hospital

Author

Achili, Y., Ades, L., Aguinaga, L., Archer, G., Benattia, A., Bercot, B., Bergeron, A., Bertinchamp, R., Bondeelle, L., Bouaziz, J.D., Bouda, D., Boutboul, D., Brindel Berthon, I., Brugnet, E., Caillat Zucman, S., Cassonnet, S., Celli Lebras, K., Chabert, J., Chaix, M.L., Chevret, S., Clément, M., Davoine, C., De Castro, N., De Kerviler, E., De Margerie-Mellon, C., Depret, F., Denis, B., Djaghout, L., Dupin, C., Farge-Blancel, D., Fauvaux, C., Fenaux, H., Feredj, E., Feyeux, D., Fremeaux-Bacchi, V., Galicier, L., Garestier, J., Harel, S., Jegu, A.L., Kozakiewicz, E., Lebel M Baye, A., Le Guen, P., Lengline, E., Liegeon, G., Lorillon, G., Madelaine Chambrin, I., Martin de Frémont, G., Maylin, S., Mehlman, C., Meunier, M., Molina, J.M., Morin, F., Oksenhendler, E., Peffault de la Tour, R., Plaud, B., Rouveau, M., Saussereau, J., Schnepf, N., Soret, J., Tazi, A., Tremorin, M.T., Peyrony, Olivier, Ellouze, Sami, Fontaine, Jean-Paul, Thegat-Le Cam, Micheline, Salmona, Maud, Feghoul, Linda, Mahjoub, Nadia, Mercier-Delarue, Séverine, Gabassi, Audrey, Delaugerre, Constance, and Le Goff, Jérôme

Published
2020
Full Text
View/download PDF

5. French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry.

Author

Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., Harel, S., Perrot, A., Bories, P., Vincent, L., Lamure, S., Mohty, M., Malard, F., Manier, S., Yakoub‐Agha, I., Schiano De Colella, J.‐M., and Brisou, G.

Subjects
CYTOKINE release syndrome, BISPECIFIC antibodies, CHIMERIC antigen receptors, PATIENT experience, MULTIPLE myeloma
Abstract

Summary: Idecabtagene vicleucel (ide‐cel), a chimeric antigen receptor T‐cell therapy targeting B‐cell maturation antigen (BCMA), received early access program (EAP) authorization in France in April 2021 for relapsed/refractory multiple myeloma (RRMM). We conducted a real‐world registry‐based multicentre observational study in 11 French hospitals to evaluate ide‐cel outcomes. Data from 176 RRMM patients who underwent apheresis between June 2021 and November 2022 were collected from the French national DESCAR‐T registry. Of these, 159 patients (90%) received ide‐cel. Cytokine release syndrome occurred in 90% with 2% grade ≥3, and neurotoxicity occurred in 12% with 3% grade ≥3. Over the first 6 months, the best overall response and ≥complete response rates were 88% and 47% respectively. The median progression‐free survival (PFS) from the ide‐cel infusion was 12.5 months, the median overall survival (OS) was 20.8 months and the estimated OS rate at 12 months was 73.3%. Patients with extra‐medullary disease (EMD) had impaired PFS (6.2 months vs. 14.8 months). On multivariable analysis, EMD and previous exposure to BCMA‐targeted immunoconjugate or T‐cell‐redirecting GPRC5D bispecific antibody were associated with inferior PFS. Our study supports ide‐cel's feasibility, safety and efficacy in real‐life settings, emphasizing the importance of screening for EMD and considering prior treatments to optimize patient selection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Teclistamab for relapsed refractory multiple myeloma patients on dialysis.

Author

Lebreton, P., Lachenal, F., Bouillie, S., Pica, G. M., Aftisse, H., Pascal, L., Montes, L., Macro, M., Johnson, N., Harel, S., Fernandez, M., De Renzis, B., Lioure, B., Lazareth, A., Javelot, M., Louni, C., Huart, A., and Perrot, A.

Subjects
CYTOKINE release syndrome, COVID-19, BISPECIFIC antibodies, GLOMERULAR filtration rate, EXTRAMEDULLARY diseases
Abstract

The article discusses the use of teclistamab, a humanized immunoglobulin bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) who are on dialysis. The study, conducted in France, included 15 dialysis-dependent RRMM patients who were treated with teclistamab. The results showed promising responses in most patients, with manageable side effects such as cytokine release syndrome and infections. The study suggests that teclistamab monotherapy could be a feasible and safe option for patients with dialysis-dependent RRMM who are typically excluded from clinical trials. [Extracted from the article]

Published
2024
Full Text
View/download PDF

8. IL-33 Expression Is Lower in Current Smokers at Both Transcriptomic and Protein Level.

Author

Faiz, A, Mahbub, RM, Boedijono, FS, Tomassen, MI, Kooistra, W, Timens, W, Nawijn, M, Hansbro, PM, Johansen, MD, Pouwels, SD, Heijink, IH, Massip, F, de Biase, MS, Schwarz, RF, Adcock, IM, Chung, KF, van der Does, A, Hiemstra, PS, Goulaouic, H, Xing, H, Abdulai, R, de Rinaldis, E, Cunoosamy, D, Harel, S, Lederer, D, Nivens, MC, Wark, PA, Kerstjens, HAM, Hylkema, MN, Brandsma, C-A, van den Berge, M, Cambridge Lung Cancer Early Detection Programme, Faiz, A, Mahbub, RM, Boedijono, FS, Tomassen, MI, Kooistra, W, Timens, W, Nawijn, M, Hansbro, PM, Johansen, MD, Pouwels, SD, Heijink, IH, Massip, F, de Biase, MS, Schwarz, RF, Adcock, IM, Chung, KF, van der Does, A, Hiemstra, PS, Goulaouic, H, Xing, H, Abdulai, R, de Rinaldis, E, Cunoosamy, D, Harel, S, Lederer, D, Nivens, MC, Wark, PA, Kerstjens, HAM, Hylkema, MN, Brandsma, C-A, van den Berge, M, and Cambridge Lung Cancer Early Detection Programme

Abstract

INTRODUCTION: IL-33 is a pro-inflammatory cytokine thought to play a role in the pathogenesis of asthma and COPD. A recent clinical trial using the anti-IL33 antibody showed a reduction in exacerbation and improved lung function in ex-smokers but not current smokers with COPD. In this study, we aimed to understand the effects of smoking status on IL-33. METHODS: We investigated the association of smoking status with the level of gene expression of IL33 in the airways in eight independent transcriptomic studies of lung airways. Additionally, we performed western blot and immunohistochemistry for IL-33 in lung tissue to assess protein levels. RESULTS: Across the bulk RNA-sequencing datasets, IL-33 gene expression and its signaling pathway were significantly lower in current- compared to ex- or never-smokers and increased upon smoking cessation (p<0.05). Single-cell sequencing showed that IL-33 is predominantly expressed in resting basal epithelial cells and decreases during the differentiation process triggered by smoke exposure. We also found a higher transitioning of this cellular sub-population into a more differentiated cell type during chronic smoking, potentially driving the reduction of IL-33. Protein analysis demonstrated lower IL-33 levels in lung tissue from COPD current- compared to ex-smokers and a lower proportion of IL-33 positive basal cells in current versus ex-smoking controls. CONCLUSION: We provide strong evidence that cigarette smoke leads to an overall reduction in IL33 expression in both transcriptomic and protein level and this may be due to the decrease in resting basal cells. Together, these findings may explain the clinical observation that a recent antibody-based anti-IL-33 treatment is more effective in ex- than current smokers with COPD. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Published
2023

9. Using Single Cell Sequencing to Understand Treatment Response to Anti-IL33 Treatment in Chronic Obstructive Pulmonary Disease (COPD)

Author

Faiz, A., primary, Mahbub, R., additional, Sabrina Boedijono, F., additional, Timens, W., additional, Nawijn, M.C., additional, Hansbro, P., additional, D. Johansen, M., additional, Brandsma, C.-A., additional, Heijink, I.H., additional, Massip, F., additional, Stella de Biase, M., additional, F. Schwarz, R., additional, Adcock, I.M., additional, Chung, K.F., additional, Hiemstra, P.S., additional, Goulaouic, H., additional, Heming Xing, H., additional, Abdulai, R.M., additional, de Rinaldis, E., additional, Cunoosamy, D., additional, Harel, S., additional, Lederer, D.J., additional, C Nivens, M., additional, Kerstjens, H.A.M., additional, Hylkema, M., additional, and Van den Berge, M., additional

Published
2023
Full Text
View/download PDF

10. B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORK

Author

Roussel, M., primary, Pirotte, M., additional, Gounot, R., additional, Queru, K., additional, Rizzo, O., additional, Royer, B., additional, Harel, S., additional, Desport, E., additional, Huart, A., additional, Niault, M., additional, Karlin, L., additional, Decaux, O., additional, Chalopin, T., additional, Carpentier, B., additional, Macro, M., additional, Vignon, M., additional, Chalayer, E., additional, Stoppa, AM., additional, Bridoux, F., additional, and Jaccard, A., additional

Published
2023
Full Text
View/download PDF

16. Sclérœdèmes de Buschke liés à une gammapathie monoclonale : série de 15 cas et revue de la littérature

Author

Hulin, M., primary, Jachiet, M., additional, Chasset, F., additional, Harel, S., additional, Royer, B., additional, Fain, O., additional, Bégon, E., additional, Carpentier, O., additional, Bessis, D., additional, Decaux, O., additional, Deroux, A., additional, Dupin, N., additional, Poiraud, C., additional, Mascaró, J.M., additional, Fernandez, D.L.C., additional, Osio, A., additional, Battistella, M., additional, Bouaziz, J.D., additional, Arnulf, B., additional, and Mahévas, T., additional

Published
2022
Full Text
View/download PDF

19. Signification clinique des gammapathies monoclonales au cours du syndrome VEXAS

Author

Stammler, R., Georgin-Lavialle, S., Terrier, B., Comont, T., Heiblig, M., Decker, P., Bouillet, L., Guédon, A.F., Bourguiba, R., Audemard-Verger, A., Hirsch, P., Fain, O., Servettaz, A., Lacombe, V., Terriou, L., Ardois, S., Bouaziz, J.D., Mathian, A., Le Guenno, G., Aouba, A., Outh, R., Meyer, A., Ebbo, M., Zhao, L.P., Bigot, A., Jamilloux, Y., Guillotin, V., Jachiet, V., Samson, M., Sujobert, P., Fenaux, P., Kosmider, O., Mekinian, A., Harel, S., and Moulinet, T.

Published
2024
Full Text
View/download PDF

20. Verbal Short-Term Memory Span in Children: Long-Term Modality Dependent Effects of Intrauterine Growth Restriction

Author

Geva, R., Eshel, R., Leitner, Y., Fattal-Valevski, A., and Harel, S.

Abstract

Background: Recent reports showed that children born with intrauterine growth restriction (IUGR) are at greater risk of experiencing verbal short-term memory span (STM) deficits that may impede their learning capacities at school. It is still unknown whether these deficits are modality dependent. Methods: This long-term, prospective design study examined modality-dependent verbal STM functions in children who were diagnosed at birth with IUGR (n = 138) and a control group (n = 64). Their STM skills were evaluated individually at 9 years of age with four conditions of the Visual-Aural Digit Span Test (VADS; Koppitz, 1981): auditory-oral, auditory-written, visuospatial-oral and visuospatial-written. Cognitive competence was evaluated with the short form of the Wechsler Intelligence Scales for Children-revised (WISC-R95; Wechsler, 1998). Results: We found IUGR-related specific auditory-oral STM deficits (p less than 0.036) in conjunction with two double dissociations: an auditory-visuospatial (p less than 0.014) and an input-output processing distinction (p less than 0.014). Cognitive competence had a significant effect on all four conditions; however, the effect of IUGR on the auditory-oral condition was not overridden by the effect of intelligence quotient (IQ). Conclusions: Intrauterine growth restriction affects global competence and inter-modality processing, as well as distinct auditory input processing related to verbal STM functions. The findings support a long-term relationship between prenatal aberrant head growth and auditory verbal STM deficits by the end of the first decade of life. Empirical, clinical and educational implications are presented.

Published
2008
Full Text
View/download PDF

21. The regulation of IL33 following smoking cessation

Author

Faiz, A, primary, Boedijono, F S, additional, Timens, W, additional, Nawijn, M, additional, Hansbro, P M, additional, Mahbub, R, additional, Johansen, M D, additional, Brandsma, C, additional, Heijink, I H, additional, Massip, F, additional, De Biase, M S, additional, Schwarz, R F, additional, Adcock, I M, additional, Chung, K F, additional, Hiemstra, P S, additional, Goulaouic, H, additional, Xing, H, additional, Abdulai, R, additional, De Rinaldis, E, additional, Cunoosamy, D, additional, Harel, S, additional, Lederer, D J, additional, Nivens, C, additional, Kerstjens, H, additional, Hylkema, M, additional, and Van Den Berge, M, additional

Published
2022
Full Text
View/download PDF

24. Pharmacokinetics and Effect on Type 2 Biomarker Levels of Dupilumab Weight Tiered-Based Dose Regimens in Patients Aged 6 to 11 Years with Uncontrolled, Moderate-to-Severe Asthma

Author

Jackson, D.J., primary, Bacharier, L.B., additional, Sher, L., additional, Domingo Ribas, C., additional, Papadopoulos, N., additional, Modena, B.D., additional, Li, N., additional, Xia, C., additional, Harel, S., additional, Wolfe, K., additional, Kamal, M., additional, Gall, R., additional, Amin, N., additional, Mannent, L., additional, Laws, E., additional, Rowe, P.J., additional, Jacob-Nara, J.A., additional, Deniz, Y., additional, Lederer, D.J., additional, Hardin, M.E., additional, and Xu, C., additional

Published
2022
Full Text
View/download PDF

25. Relation Between Fractional Exhaled Nitric Oxide Reductions and Efficacy Outcomes in Patients with Asthma Treated with Dupilumab

Author

Busse, W., primary, Pavord, I.D., additional, Deniz, Y., additional, Casale, T.B., additional, Wenzel, S.E., additional, Corren, J., additional, Fitzgerald, J.M., additional, Daizadeh, N., additional, Jagerschmidt, A., additional, Harel, S., additional, Ortiz, B., additional, Djandji, M., additional, Crikelair, N., additional, Jacob-Nara, J.A., additional, and Rowe, P.J., additional

Published
2022
Full Text
View/download PDF

28. DOP72 The association of anti-tumor necrosis factor and thiopurine therapy with the risk of lymphoma among Inflammatory Bowel Disease patients: A nation-wide study from the epi-IIRN

Author

Waterman, M, primary, Lavi, I, additional, Harel, S, additional, Focht, G, additional, Loewenberg Weisband, J, additional, Greenfeld, S, additional, Kariv, R, additional, Ledderman, N, additional, Matz, E, additional, Keinan-Boker, L, additional, Eizenstein, S, additional, Dotan, I, additional, Turner, D, additional, and Levi, Z, additional

Published
2022
Full Text
View/download PDF

31. Le traitement anti-plasmocytaire entraîne une réponse clinico-biologique durable chez les patients atteints d’un scléromyxoedème en rechute ou avec une forme extra-cutanée sévère et un sevrage des immunoglobulines intra-veineuses

Author

Theves, F., Lahuna, C., Mahévas, T., Harel, S., Royer, B., Lemiale, V., Brignier, A., Parquet, N., Jachiet, M., Bouaziz, J.D., Elessa, D., Arnulf, B., and Talbot, A.

Abstract

Le scléromyxoedeme (SM) est une mucinose primaire systémique très fréquemment associée à une gammapathie monoclonale appartenant au spectre des gammapathies monoclonales de signification clinique et cutanée. Les immunoglobulines intra-veineuses (IgIV) données à 2g/kg/cure mensuelle sont le traitement de première intention. Néanmoins, certains patients rechutent ou sont dépendants de fortes doses d’immunoglobulines, ou présentent des complications sévères extra-cutanées comme le dermato neuro-syndrome ou les atteintes cardiaques (cardiomyopathie hypertrophique).

Published
2024
Full Text
View/download PDF

32. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19

Author

Archer, G., Benattia, A., Bergeron, A., Bondeelle, L., Bouaziz, J.D., Bouda, D., Boutboul, D., Brindel, Berthon I., Bugnet, E., Caillat Zucman, S., Cassonnet, S., Celli Lebras, K., Chabert, J., Chevret, S., Clément, M., Davoine, C., De Castro, N., De Kerviler, E., De Margerie-Mellon, C., Delaugerre, C., Depret, F., Denis, B., Djaghout, L., Dupin, C., Farge-Bancel, D., Fauvaux, C., Feredj, E., Feyeux, D., Fontaine, J.P., Fremeaux-Bacchi, V., Galicier, L., Harel, S., AL, Jegu, Kozakiewicz, E., Lebel, M., Baye, A., Le Goff, J., Le Guen, P., Lengline, E., Liegeon, G., Lorillon, G., Madelaine Chambrin, I., Martin de Frémont, G., Meunier, M., Molina, J.M., Morin, F., Oksenhendler, E., Peffault de la Tour, R., Peyrony, O., Plaud, B., Salmona, M., Saussereau, J., Soret, J., Delaleu, Jérémie, Deniau, Benjamin, Battistella, Maxime, de Masson, Adèle, Bensaid, Benoit, Jachiet, Marie, Lazaridou, Ingrid, Bagot, Martine, and Bouaziz, Jean-David

Published
2020
Full Text
View/download PDF

39. 405 Dupilumab normalizes expression of type 2 inflammatory genes

Author

Hamilton, J.D., primary, Collins, M.H., additional, Lim, W., additional, Hamon, S., additional, Wipperman, M.F., additional, Radin, A., additional, Chehade, M., additional, Hirano, I., additional, Dellon, E.S., additional, Harel, S., additional, Patel, K., additional, and Rothenberg, M.E., additional

Published
2021
Full Text
View/download PDF

42. Prognostic value of cardio-pulmonary exercise testing in cardiac amyloidosis

Author

Nicol, M., primary, Deney, A., additional, Lairez, O., additional, Vergaro, G., additional, Emdin, M., additional, Inamo, J., additional, Montfort, A., additional, Damy, T., additional, Harel, S., additional, Royer, B., additional, Baudet, M., additional, Cohen Solal, A., additional, Arnulf, B., additional, and Logeart, D., additional

Published
2021
Full Text
View/download PDF

46. 1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres

Author

Aguinaga, L., primary, Ursu, R., additional, Legoff, J., additional, Delauguerre, C., additional, Nguyen, O., additional, Harel, S., additional, Royer, B., additional, sebert, M., additional, Jachiet, M., additional, Lebbé, C., additional, Bonnet, C., additional, Brice, P., additional, Fenaux, P., additional, Plaud, B., additional, and Aparicio, T., additional

Published
2020
Full Text
View/download PDF

47. Surfaces and equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the emergency department at a university hospital

Author

Peyrony, Olivier, primary, Ellouze, Sami, additional, Fontaine, Jean-Paul, additional, Thegat-Le Cam, Micheline, additional, Salmona, Maud, additional, Feghoul, Linda, additional, Mahjoub, Nadia, additional, Mercier-Delarue, Séverine, additional, Gabassi, Audrey, additional, Delaugerre, Constance, additional, Le Goff, Jérôme, additional, Achili, Y., additional, Ades, L., additional, Aguinaga, L., additional, Archer, G., additional, Benattia, A., additional, Bercot, B., additional, Bergeron, A., additional, Bertinchamp, R., additional, Bondeelle, L., additional, Bouaziz, J.D., additional, Bouda, D., additional, Boutboul, D., additional, Brindel Berthon, I., additional, Brugnet, E., additional, Caillat Zucman, S., additional, Cassonnet, S., additional, Celli Lebras, K., additional, Chabert, J., additional, Chaix, M.L., additional, Chevret, S., additional, Clément, M., additional, Davoine, C., additional, De Castro, N., additional, De Kerviler, E., additional, De Margerie-Mellon, C., additional, Depret, F., additional, Denis, B., additional, Djaghout, L., additional, Dupin, C., additional, Farge-Blancel, D., additional, Fauvaux, C., additional, Fenaux, H., additional, Feredj, E., additional, Feyeux, D., additional, Fremeaux-Bacchi, V., additional, Galicier, L., additional, Garestier, J., additional, Harel, S., additional, Jegu, A.L., additional, Kozakiewicz, E., additional, Lebel M Baye, A., additional, Le Guen, P., additional, Lengline, E., additional, Liegeon, G., additional, Lorillon, G., additional, Madelaine Chambrin, I., additional, Martin de Frémont, G., additional, Maylin, S., additional, Mehlman, C., additional, Meunier, M., additional, Molina, J.M., additional, Morin, F., additional, Oksenhendler, E., additional, Peffault de la Tour, R., additional, Plaud, B., additional, Rouveau, M., additional, Saussereau, J., additional, Schnepf, N., additional, Soret, J., additional, Tazi, A., additional, and Tremorin, M.T., additional

Published
2020
Full Text
View/download PDF

48. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19

Author

Delaleu, Jérémie, primary, Deniau, Benjamin, additional, Battistella, Maxime, additional, de Masson, Adèle, additional, Bensaid, Benoit, additional, Jachiet, Marie, additional, Lazaridou, Ingrid, additional, Bagot, Martine, additional, Bouaziz, Jean-David, additional, Archer, G., additional, Benattia, A., additional, Bergeron, A., additional, Bondeelle, L., additional, Bouaziz, J.D., additional, Bouda, D., additional, Boutboul, D., additional, Brindel, Berthon I., additional, Bugnet, E., additional, Caillat Zucman, S., additional, Cassonnet, S., additional, Celli Lebras, K., additional, Chabert, J., additional, Chevret, S., additional, Clément, M., additional, Davoine, C., additional, De Castro, N., additional, De Kerviler, E., additional, De Margerie-Mellon, C., additional, Delaugerre, C., additional, Depret, F., additional, Denis, B., additional, Djaghout, L., additional, Dupin, C., additional, Farge-Bancel, D., additional, Fauvaux, C., additional, Feredj, E., additional, Feyeux, D., additional, Fontaine, J.P., additional, Fremeaux-Bacchi, V., additional, Galicier, L., additional, Harel, S., additional, AL, Jegu, additional, Kozakiewicz, E., additional, Lebel, M., additional, Baye, A., additional, Le Goff, J., additional, Le Guen, P., additional, Lengline, E., additional, Liegeon, G., additional, Lorillon, G., additional, Madelaine Chambrin, I., additional, Martin de Frémont, G., additional, Meunier, M., additional, Molina, J.M., additional, Morin, F., additional, Oksenhendler, E., additional, Peffault de la Tour, R., additional, Peyrony, O., additional, Plaud, B., additional, Salmona, M., additional, Saussereau, J., additional, and Soret, J., additional

Published
2020
Full Text
View/download PDF

49. Dupilumab Efficacy in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma by Baseline IgE and Thymus and Activation Regulated Chemokine Levels from the Pooled Population of the SINUS-24 and SINUS-52 Phase 3 Trials

Author

Maspero, J.F., primary, Bachert, C., additional, Canonica, G.W., additional, Swanson, B.N., additional, Cho, S.H., additional, Harel, S., additional, Jagerschmidt, A., additional, Zhang, M., additional, Mao, X., additional, Mannent, L.P., additional, and Amin, N., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results